Purine supplements for AICA-ribosiduria
Part of Genetic & congenital clinical trials.
This trial tests whether adding purines (natural substances found in foods) to your diet can help treat AICA-ribosiduria, a rare genetic condition. It may be a safe and simple therapy option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of AICA-ribosiduria due to a problem with the ATIC enzyme.
- You should not already be eating a diet high in purines (substances found in certain foods), as this could be a problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
This trial tests whether a diet high in carbohydrates can help treat acute intermittent porphyria (AIP), a condition that can cause attacks of pain and other symptoms. If you have AIP, this study wants to see if eating more carbs can prevent or manage attacks.
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The treatment aims to reduce kidney damage, and this study will help determine if it is safe and effective.
This trial tests a gene therapy given by infusion that aims to replace the faulty gene causing aspartylglucosaminuria (AGU), a rare inherited condition affecting the brain and body. The goal is to see if it's safe and can slow or improve symptoms.
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Hear when a new AICA-ribosiduria Due to ATIC Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.